Lucid Total Current Assets from 2010 to 2024

LUCD Stock  USD 0.91  0.02  2.25%   
Lucid Diagnostics' Total Current Assets are increasing over the years with slightly volatile fluctuation. Total Current Assets are expected to dwindle to about 19.4 M. Total Current Assets is the total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle. View All Fundamentals
 
Total Current Assets  
First Reported
2010-12-31
Previous Quarter
22.1 M
Current Value
19.4 M
Quarterly Volatility
16.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lucid Diagnostics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lucid main balance sheet or income statement drivers, such as Interest Expense of 436.8 K, Tax Provision of 0.0 or Depreciation And Amortization of 2.7 M, as well as many exotic indicators such as Price To Sales Ratio of 23.04, Dividend Yield of 0.0 or Days Sales Outstanding of 12.77. Lucid financial statements analysis is a perfect complement when working with Lucid Diagnostics Valuation or Volatility modules.
  
This module can also supplement various Lucid Diagnostics Technical models . Check out the analysis of Lucid Diagnostics Correlation against competitors.
For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.

Latest Lucid Diagnostics' Total Current Assets Growth Pattern

Below is the plot of the Total Current Assets of Lucid Diagnostics over the last few years. It is the total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle. Lucid Diagnostics' Total Current Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lucid Diagnostics' overall financial position and show how it may be relating to other accounts over time.
Total Current Assets10 Years Trend
Slightly volatile
   Total Current Assets   
       Timeline  

Lucid Total Current Assets Regression Statistics

Arithmetic Mean8,338,628
Geometric Mean208,278
Coefficient Of Variation194.91
Mean Deviation11,964,524
Median17,800
Standard Deviation16,252,419
Sample Variance264.1T
Range57.3M
R-Value0.61
Mean Square Error177.6T
R-Squared0.38
Significance0.02
Slope2,226,950
Total Sum of Squares3698T

Lucid Total Current Assets History

202419.4 M
202322.1 M
202224.4 M
202157.3 M
20201.4 M
2019390.9 K

About Lucid Diagnostics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Lucid Diagnostics income statement, its balance sheet, and the statement of cash flows. Lucid Diagnostics investors use historical funamental indicators, such as Lucid Diagnostics's Total Current Assets, to determine how well the company is positioned to perform in the future. Although Lucid Diagnostics investors may use each financial statement separately, they are all related. The changes in Lucid Diagnostics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Lucid Diagnostics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Lucid Diagnostics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Lucid Diagnostics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Current Assets22.1 M19.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Lucid Diagnostics is a strong investment it is important to analyze Lucid Diagnostics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lucid Diagnostics' future performance. For an informed investment choice regarding Lucid Stock, refer to the following important reports:
Check out the analysis of Lucid Diagnostics Correlation against competitors.
For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.
Note that the Lucid Diagnostics information on this page should be used as a complementary analysis to other Lucid Diagnostics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Lucid Stock analysis

When running Lucid Diagnostics' price analysis, check to measure Lucid Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lucid Diagnostics is operating at the current time. Most of Lucid Diagnostics' value examination focuses on studying past and present price action to predict the probability of Lucid Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lucid Diagnostics' price. Additionally, you may evaluate how the addition of Lucid Diagnostics to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Bonds Directory
Find actively traded corporate debentures issued by US companies
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Is Lucid Diagnostics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lucid Diagnostics. If investors know Lucid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lucid Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.26)
Revenue Per Share
0.07
Quarterly Revenue Growth
1.244
Return On Assets
(0.69)
Return On Equity
(2.56)
The market value of Lucid Diagnostics is measured differently than its book value, which is the value of Lucid that is recorded on the company's balance sheet. Investors also form their own opinion of Lucid Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Lucid Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lucid Diagnostics' market value can be influenced by many factors that don't directly affect Lucid Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lucid Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lucid Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lucid Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.